Willkommen, schön sind Sie da!
Logo Ex Libris

Macromolecular Anticancer Therapeutics

  • Kartonierter Einband
  • 644 Seiten
(0) Erste Bewertung abgeben
Alle Bewertungen ansehen
This book details the macromolecular therapeutics for cancer therapy. It also covers the classification of these anticancer drugs ... Weiterlesen
CHF 346.00
Print on Demand - Auslieferung erfolgt in der Regel innert 4 bis 6 Wochen.
Bestellung & Lieferung in eine Filiale möglich


This book details the macromolecular therapeutics for cancer therapy. It also covers the classification of these anticancer drugs based on therapeutic targets and elaborates on different classes of anticancer therapeutics.

In spite of the development of various anticancer drugs, the therapy of cancer has remained challenging for decades. The current therapy of cancer is overwhelmed because of the inability to deliver therapeutics to all regions of a tumor in effective therapeutic concentrations, intrinsic or acquired resistance to the treatment with currently available agents via genetic and epigenetic mechanisms, and toxicity. As a result, cancer therapy using conventional therapeutics and different types of treatment regimens using this therapeutics has not led to a convincing survival benefit of the patients. In this context, Macromolecular therapeutics offer several advantages over conventional low molecular therapeutics by various ways such as, enable the use of larger doses of these agents by limiting the toxicity, by enhanced permeability and retention into tumors, by tumor targeting using tumor-specific antibodies, by specific inhibition of oncogenes using anticancer oligonucleotides etc. Cancer treatment using this macromolecular therapeutics has considerably improved the survival benefit for patients. As a result, various macromolecular therapeutics are already commercialized or are under clinical development. Although we are far from a real magic bullet today, looking at the pace of research and current success in this field of macromolecular therapeutics, it appears that we are approaching a magic bullet for the efficient treatment of cancer. Thus, we believe that the subject of this book is very timely, and that the book will fill an unmet need in the market.

This book is unique and assembles various types and aspects of macromolecular anticancer therapeutics for cancer therapy in one shell and conveys the importance of this interdisciplinary field to the broad audience. Thus, in a nutshell, this book details the basics of cancer, and various therapeutic strategies such as those based on macromolecular therapeutics hence can become an important reference for practitioners, oncologists, medical pharmacologists, medicinal chemists, biomedical scientists, experimental pharmacologists, pharmaceutical technologists, and particularly it can essentially become a handbook of macromolecular therapeutics for cancer therapy for graduates, post-graduates and Ph.D. students in these fields.

Macromolecular anticancer therapeutics encompasses macromolecule-conjugated anticancer prodrugs or macromolecules themselves for the treatment of cancer

Emphasizes various types and aspects of macromolecular anticancer therapeutics such as polymer-based anticancer therapeutics, antibody-directed anticancer therapeutics, lipid-based anticancer therapeutics and nucleic acid therapeutics (see table of contents)

Various chapters in this book are to be written by pioneer scientists and experts in the respective fields


L. Harivardhan Reddy is Head of Nanovectors group at Sanofi-aventis, France. He completed Ph.D. in Pharmaceutics and Drug delivery in 2005 from The M.S. University of Baroda, India. He has worked for 4 years in two popular pharmaceutical companies (Sun Pharmaceutical Industries Ltd., and Aristo Pharmaceuticals Ltd.) in India, on drug delivery applications. He worked for 3 years (2005-2008) with anticancer drug delivery specialist Prof. Patrick Couvreur in CNRS lab at Université Paris-Sud, Chatenay-Malabry, France. He is an inventor of 3 patents belonging to macromolecular therapeutics and drug delivery. He has published, as an author and co-author, more than 60 publications in various reputed journals. He is also a reviewer for more than 15 journals of the fields of biomacromolecules, drug delivery, cancer therapy, and pharmacology. He is a member of The European Association for Cancer Research. His principal research interests are supramolecular lipidic prodrug nanomedicines and nanotherapeutics for cancer.

Patrick Couvreur is a Full Professor of Pharmacy at the University Paris-Sud, France, and holder of the chair of "Innovation Technologique" (2009-2010) at the prestigious 'Collège de France'. He is a member of the Academy of Technologies (France), of the Academy of Pharmacy (France) and corresponding member of the Royal Academy of Medicine (Belgium). Prof. Patrick COUVREUR's contributions in the field of drug delivery and targeting are highly recognized and respected around the world. Patrick COUVREUR performed a pioneer work together with Peter SPEISER, and demonstrated for the first time in 1977 that nanoparticles may be used as intracellular carriers for compounds which don't diffuse spontaneously into cells. Patrick COUVREUR's research is primarily on polymer-based and metallic-based nanomedicines, surface engineered nanosystems, and also focuses on lipid-based nanocarriers. He has published as an author and co-author, 341 publications, 109 review articles and book chapters, 6 books as editor, 50 patents, and 193 invited and plenary lectures at national and international congresses. He has received Pharmaceutical Sciences World Congress Award (2004), the "Marie-Maurice Janot Lecture" (2008) and above all the prestigious "Host Madsen Medal" (2007) in honour of his outstanding research achievements. He is a Field Editor of "Pharmaceutical Research", European Editor of the "Journal of Nanoparticles Research", and is a reviewer of more than 15 high reputed journals in the fields of Drug delivery, cancer research, macromolecules, physical chemistry etc. He is acting or acted as Board of Governors of the Controlled Release Society (CRS), Board of APGI, Expert Member of the Board of Pharmaceutical Sciences, International Pharmaceutical Federation (FIP). His exceptional research has led to two start-up companies BIOALLIANCE and MEDSQUAL dealing with novel therapeutics, in France.


The field of macromolecular therapeutics for cancer therapy is of considerable importance, as these therapeutic systems are gaining more and more interest to give new directions for the treatment of this dreadful disease. Macromolecular Anticancer Therapeutics, which describes in detail the macromolecular therapeutics for cancer therapy, covers the classification of these anticancer drugs based on therapeutic targets, and elaborates on different classes of anticancer therapeutics which are either in pre-clinic or in clinical phases or are already commercialized. This book also discusses various signal transduction pathways involved in the cancer growth and resistance to therapy, providing a clear insight into the molecular mechanistic aspects of this topic; it also describes the essential targets for efficient cancer therapy. In detail, this volume elaborates the different categories of macromolecular therapeutics of respectively natural and synthetic polymer and lipid origin, their chemistry, design and development, opportunities and challenges, current status, pre-clinic and clinical progresses. In addition, the design, development, and the challenges involved in future directions for cancer therapy using various categories of antibody-based therapeutics are elaborated in areas such as antibody-mediated drug targeting to cancer employing antibody-drug conjugates, radioimmunoconjugates, toxin-antibody conjugates, antibody-mediated enzyme pro-drug therapeutics, and also using antibodies alone to interfere with specific molecular targets responsible for tumor growth and progression. Besides the current status, pre-clinic and clinical progress of a variety of therapeutic anticancer oligonucleotides and siRNA designed and developed for specific inhibition of oncogenes are detailed. Furthermore, in this book, special attention is given to the treatment of breast cancer based on a comprehensive description about molecular mechanisms involved, hormone receptors implicated and molecular therapeutic interventions.

Macromolecular Anticancer Therapeutics details the current macromolecular therapeutic strategies, and should become an important reference for practitioners, oncologists, medical pharmacologists, medicinal chemists, biomedical scientists, experimental pharmacologists and pharmaceutical technologists. It is also a reference concerning macromolecular cancer therapy for graduates, post-graduates and Ph.D. students belonging to these fields.


I. Synthetic polymer-based anticancer prodrugs

Jindrich Kopecek (Departments of Pharmaceutics and Pharmaceutical Chemistry and of Bioengineering, University of Utah, Salt Lake City, Utah 84112)

HPMA-anticancer drug conjugates

Richard B. Greenwald (Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, New Jersey 00854)

Poly(ethylene glycol)-anticancer drug conjugates

Chun Li (Department of Experimental Diagnostic Imaging, Box 59, The University of Texas, M.D. Anderson Cancer Center,

1515 Holcombe Blvd., Houston, TX 77030, USA)

Poly(L-glutamic acid)-anticancer drug conjugates

II. Natural polymer-based anticancer prodrugs

Felix Kratz (Department of Medical Oncology, Clinical Research, Tumor Biology Center, Breisacher Straße 117, D-79106 Freiburg, Federal Republic of Germany)

Protein-based anticancer conjugates

Andrew V. Schally (Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, Louisiana)

Peptide and peptide hormone anticancer therapeutics

Yoshiharu Machida (Department of Drug Delivery Research, Hoshi University; 2441 Ebara, Shinagawa-ku, Tokyo 1428501, Japan)

Chitosan and other polysaccharide anticancer conjugates

III. Antibody-directed cancer therapy

John R. Desjarlais

Xencor, Inc. CA 91016, United States

Engineering of antitumor antibodies

Victor S. Goldmacher (ImmunoGen Inc., 128 Sidney Street, Cambridge, MA 02139-4239, USA)

Antibody-anticancer drug conjugates

David M. Goldenberg (Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA.)

Immunoconjugate and radioimmunoconjugate anticancer therapeutics

Kenneth D. Bagshawe (Imperial College London, Department of Medical Oncology, Charing Cross Campus, Fulham Palace Road, London W6 8RF, UK.)

Antibody-directed enzyme prodrug anticancer therapeutics

Paul M. Harari (University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, WI 53792, USA.)

EGFR-directed monoclonal antibodies

Gabriel N. Hortobagyi (Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX. usa)

Her2/neu-directed antibodies

John M. Kirkwood (Division of Hematology-Oncology, Department of Medicine, Hillman Cancer Center, Pittsburgh, PA 15232)

CTLA-4-directed monoclonal antibodies

Dario Neri (Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland)

Antibodies directed to tumor vasculature

IV. Lipid-based anticancer prodrugs

L. Harivardhan Reddy, Patrick Couvreur (Physicochimie, Pharmacotechnie et Biopharmacie, Faculty of Pharmacy, Universite Paris-Sud XI, Chatenay-Malabry, France)

Lipid-based prodrugs of anti-metabolite anticancer agents

Mitsuru Hashida (Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan)

Lipid-based prodrugs of non-anti-metabolite anticancer agents

V. Macromolecular nucleic acid therapeutics

Ernst Wagner (Pharmaceutical Biology-Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universitaet, Butenandtstr. 513, D-81377, Muenchen, Germany)

Macromolecular nucleic acid therapeutics

Uwe Zangemeister-Wittke (Department of Pharmacology, University of Bern, Bern, Switzerland.)

Antisense oligonucleotides

Brett P. Monia (Isis Pharmaceuticals, California 92008, USA)

Therapeutic MicroRNAs

Mark A. Behlke (Integrated DNA Technologies Inc., Coralville, IA 52241, USA)

Therapeutic siRNAs


Titel: Macromolecular Anticancer Therapeutics
EAN: 9781461424925
ISBN: 1461424925
Format: Kartonierter Einband
Herausgeber: Springer New York
Genre: Medizin
Anzahl Seiten: 644
Gewicht: 961g
Größe: H235mm x B155mm x T34mm
Jahr: 2012
Auflage: 2010